ABL1 and leukemia: In summary, NUP98-PMX1;Abl1−/− cells were highly sensitive to PI3K and mTOR inhibitors when compared to the Abl1 + /+ counterparts, and imatinib sensitized Abl1 + /+ leukemia cells to PI3K inhibitor buparlisib.